Aclaris Therapeutics (ACRS) vs Monopar Therapeutics (MNPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aclaris Therapeutics (ACRS) has outperformed Monopar Therapeutics (MNPR) over the past year, gaining 84.8% versus a loss of 15.0%. Over five years, MNPR leads with a +241.3% price change compared with -79.8% for ACRS. Monopar Therapeutics is the larger company by market cap ($562.3 million vs $500.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRS | MNPR |
|---|---|---|
| Share price | $3.40 | $83.78 |
| Market cap | $500.48M | $562.35M |
| 1-day change | -8.11% | +5.29% |
| YTD return | +12.96% | +28.30% |
| 1-year return | +84.78% | -14.96% |
| 5-year return | -79.77% | +241.26% |
| EPS (TTM) | $-0.58 | $-2.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.60 | $124.82 |
| 52-week low | $1.74 | $50.07 |
| Distance from 52-week high | -48.48% | -32.88% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +199.41% | +55.07% |
| Average volume | 2.48M | 215.52K |
| Shares outstanding | 147.20M | 6.71M |
| Employees | 69 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRS has outperformed MNPR by 99.7 percentage points over the past year.
About Aclaris Therapeutics
ACRS stock →Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Monopar Therapeutics
MNPR stock →Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
ACRS vs MNPR FAQ
Which is bigger, Aclaris Therapeutics or Monopar Therapeutics?
Monopar Therapeutics (MNPR) is larger, with a market capitalization of $562.35M compared with $500.48M for Aclaris Therapeutics (ACRS).
Which stock has performed better over the past year, ACRS or MNPR?
ACRS returned +84.78% over the past 12 months, compared with -14.96% for MNPR (price return, excluding dividends). Past performance does not predict future results.
Are Aclaris Therapeutics and Monopar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.